Zepbound denials: what the review data shows
Independent reviewers have decided 574 published cases where an insurer denied Zepbound — and they overturned the insurer 92.3% of the time. A denial for Zepbound is a starting position, not a final answer.
By condition
Why plans deny Zepbound — and how appeals win
Zepbound (tirzepatide) is FDA-approved for: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity. Denials that treat an on-label prescription as unproven or cosmetic are the ones reviewers reverse most readily.
“Weight-loss drugs excluded” boilerplate
The most common Zepbound denial isn't about you at all — it's a category exclusion of anti-obesity medication. But Zepbound is also FDA-approved for obstructive sleep apnea in adults with obesity, an indication a “cosmetic” exclusion was never written to reach.
Sleep-apnea indication ignored
Plans processing Zepbound requests under their weight-loss criteria sometimes never evaluate the OSA indication the prescriber actually wrote. If you have documented sleep apnea, a denial that analyzed the wrong indication is procedurally defective.
Step therapy and “try Wegovy first”
Some formularies prefer one GLP-1 and demand failure of it before covering another. Prescriber documentation of tolerability problems, plateaued response, or clinical reasons for tirzepatide specifically is what exception processes exist for.
BMI and comorbidity documentation
As with other anti-obesity medication, approvals turn on chart-documented BMI and weight-related comorbidities. Thin documentation — not thin evidence — drives many first-round denials.
“Fail another drug first” requirements have a formal exit: the step-therapy exception. Prior GLP-1 intolerance, contraindications, or documented clinical rationale for tirzepatide are the standard grounds, and plans must decide exception requests quickly.
What winning Zepbound appeals argue
- Lead with the strongest on-label indication you qualify for. Documented obstructive sleep apnea plus obesity is an FDA-approved use that sidesteps “weight-loss exclusion” reasoning entirely.
- Attach sleep-study results, comorbidity documentation, and BMI history so the reviewer sees a chronic-disease case, not a lifestyle request.
- If the plan preferred a different GLP-1, have your prescriber state specifically why tirzepatide — dual GIP/GLP-1 action, prior semaglutide outcome, tolerability — is the appropriate agent.
- Demand the criteria document the denial applied; a denial that applied weight-loss criteria to an OSA prescription reviewed the wrong question.
The published record backs the effort: 574 external-review decisions on Zepbound denials, 92.3% overturned. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Zepboundwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY